NCT06693674View on ClinicalTrials.gov

Effect of Sacubitril-Valsartan on Cardiac Structure and Function

PHASE3RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Congenital Heart Disease
Interventions
DRUG

Entresto Pill

Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).

OTHER

Placebo

Patients taking placebo tablets will take 1 tablet orally, twice daily

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER

NCT06693674 - Effect of Sacubitril-Valsartan on Cardiac Structure and Function | Biotech Hunter | Biotech Hunter